Market Cap: $76.41M
CI
Cumberland Pharmaceuticals Inc.
CPIX
NASDAQ (NASDAQ Global Select)USD
Market Cap: $76.41M
Cumberland Pharmaceuticals Inc. (Ticker: CPIX) presents significant advancements in its research on ifetroban, a drug that may transform the treatment of cardiomyopathy in patients with Duchenne muscu…
Cumberland Pharmaceuticals Inc. (Ticker: CPIX) announces significant advancements in cancer treatment with the positive results from a Phase 2a clinical trial of ifetroban. This investigational drug a…
Cumberland Pharmaceuticals Inc. announces a major strategic agreement with Apotex, paving the way for a substantial integration of their branded pharmaceutical businesses in the U.S. The deal, valued…
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) has received FDA approval for an expanded indication for its flagship ibuprofen product, Caldolor®. This approval allows Caldolor to be utilized for mana…
Cumberland Pharmaceuticals Enhances CINV Management Through New Sancuso® Website Cumberland Pharmaceuticals Inc., a Nashville-based specialty pharmaceutical company, has recently launched a revamped w…
Cumberland Pharmaceuticals Focuses on Healthcare Innovation Amid Anticipated Earnings Reports in Broader Economy As the healthcare sector continues to evolve, Cumberland Pharmaceuticals sees significa…
Talicia's National Launch: A Collaborative Approach to Combat H. pylori Infections Cumberland Pharmaceuticals Inc. is poised to make significant strides in the gastrointestinal treatment sector throug…
Strategic Launch of Talicia Paves Way for Enhanced H. pylori Treatment in the U.S. Cumberland Pharmaceuticals Inc. collaborates with RedHill Biopharma Ltd. to launch a national sales initiative for Ta…
Headline: FDA Fast Track speeds Cumberland’s bid to treat Duchenne cardiomyopathy Cumberland Pharmaceuticals says the U.S. Food and Drug Administration grants Fast Track Designation to ifetroban, its…
Ifetroban wins Fast Track for DMD cardiomyopathy Cumberland Pharmaceuticals announces that the U.S. Food and Drug Administration grants Fast Track Designation to its oral thromboxane receptor antagoni…
Cumberland Pharmaceuticals Secures Permanent J-Code for Caldolor, Enhancing Non-Opioid Pain Management Cumberland Pharmaceuticals Inc. announces a pivotal update for its flagship product, Caldolor® (i…
Cumberland Pharmaceuticals Expands Portfolio and Strengthens Market Position Cumberland Pharmaceuticals Inc., a Nashville-based specialty pharmaceutical company, reports a solid performance in Q3 2025…
Cumberland Pharmaceuticals Expands Portfolio with Strategic Partnerships and New Product Launch Cumberland Pharmaceuticals Inc., a Nashville-based specialty pharmaceutical company, reports a successfu…
Cumberland Pharmaceuticals and RedHill Biopharma Forge Strategic Partnership for Talicia® Cumberland Pharmaceuticals Inc. announces a significant strategic partnership with RedHill Biopharma Ltd. to c…
Cumberland Pharmaceuticals Expands Access to Vibativ® through National Agreement Cumberland Pharmaceuticals Inc., a Nashville-based specialty pharmaceutical company, has recently secured a significant…
Cumberland Pharmaceuticals Advances Non-Opioid Pain Management in Mexico Cumberland Pharmaceuticals Inc., a Nashville-based specialty pharmaceutical company, secures regulatory approval in Mexico for…
Cumberland Pharmaceuticals Secures Regulatory Approval for Injectable Ibuprofen in Mexico Cumberland Pharmaceuticals Inc., a Nashville-based specialty pharmaceutical company, marks a significant miles…
Cumberland Pharmaceuticals Expands Portfolio with New Product Launch Cumberland Pharmaceuticals, a specialty pharmaceutical company, announces the launch of a new intravenous (IV) formulation that bro…